Biological agents for moderately to severely active ulcerative colitis

Annals of Internal Medicine

Volumn 160, Issue 10, 2014, Pages 704-711

  Danese, Silvio ^a   Fiorino, Gionata ^a   Peyrin Biroulet, Laurent ^b   Lucenteforte, Ersilia ^c   Virgili, Gianni ^c   Moja, Lorenzo ^d   Bonovas, Stefanos ^e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

^d IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; VEDOLIZUMAB;

COMPARATIVE EFFECTIVENESS; HUMAN; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIAS (EPIDEMIOLOGY); BIOLOGICAL FACTORS; COLITIS, ULCERATIVE; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901257923     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2403     Document Type: Review

References (39)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-25. [PMID: 22047562]
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-17. [PMID: 15168363]
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-57. [PMID: 17499606]
4. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al; European Crohn's and Colitis Organisation (ECCO). European evidencebased Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194]
5. Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, et al; European Crohn's and Colitis Organisation (ECCO). European evidencebased consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62. [PMID: 21172195]
6. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23. [PMID: 20068560]
7. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-Analysis. BMJ. 2013;346:f2914. [PMID: 23674332]
8. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17:279-301. [PMID: 17925316]
9. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897-900. [PMID: 16223826]
10. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-24. [PMID: 15449338]
11. Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for the treatment of moderately-to-severely active ulcerative colitis in adults: a network meta-Analysis of randomised controlled trials [study protocol]. PROSPERO 2013:CRD42013005459. Accessed at www.crd .york.ac.uk/PROSPERO/display-record.asp?ID-CRD42013005459 on 20 February 2014.
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9. [PMID: 19622511]
13. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-Analysis. Ann Intern Med. 2013;159:130-7. [PMID: 23856683]
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9. [PMID: 3317057]
15. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2009. Accessed at www.cadth.ca/media/pdf/H0462-itc-tre.pdf on 20 February 2014.
16. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making. 2011 (last updated April 2012). Accessed at www.nicedsu.org.uk/TSD1%20 Introduction.final. 08.05.12.pdf on 20 February 2014.
17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-9. [PMID: 11072960]
18. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217]
19. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000; 10:325-37.
20. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76. [PMID: 16339095]
21. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-7. [PMID: 21209123]
22. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.e1-3. [PMID: 22062358]
23. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-5. [PMID: 23735746]
24. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al; PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1. [PMID: 23770005]
25. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710. [PMID: 23964932]
26. A study of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis [clinical trial]. ClinicalTrials.gov Identifier: NCT00853099. Accessed at http://clinicaltrials.gov/show/NCT00853099 on 20 February 2014.
27. Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283-94. [PMID: 24363029]
28. U.S. Food and Drug Administration. FDA GIDAC briefing document on Humira (adalimumab). Gastrointestinal Drugs Advisory Committee Meeting, BLA 125057/232. 28 August 2012. Accessed at www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Gastrointestinal DrugsAdvisoryCommittee/ UCM316786.pdf on 20 February 2014.
29. Feagan BG, Rutgeerts PJ, Sands BE. Vedolizumab induction therapy for ulcerative colitis: results of GEMINI 1, a randomized, placebo-controlled, double-blind, multicenter, phase III trial. Presented at Digestive Disease Week, San Diego, CA, 19-22 May 2012. Abstract no. 943b.
30. Rutgeerts P. Vedolizumab induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial. 20th United European Gastroenterology Week, Amsterdam, the Netherlands, 20-24 October 2012. Abstract no. OP280.
31. Feagan BG, Rutgeerts P, Sands BE, Sandborn WJ, Colombel JF, Hanauer S, et al. Vedolizumab maintenance therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Am J Gastroenterol. 2012;107:S609.
32. Takeda submits marketing authorisation application for vedolizumab in moderately to severely active ulcerative colitis and Crohn's disease in the European Union [press release]. Osaka, Japan: Takeda; 7 March 2013. Accessed at www.takeda.com/news/2013/20130308-5677.html on 20 February 2014.
33. Takeda submits biologics license application for a new investigational drug vedolizumab, in moderately to severely active Crohn's disease and ulcerative colitis in the United States [press release]. Osaka, Japan: Takeda; 21 June 2013. Accessed at www.takeda.com/news/2013/20130624-5844.html on 20 February 2014.
34. Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-toseverely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37: 204-13. [PMID: 23173821]
35. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1:e9. [PMID: 16871331]
36. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65. [PMID: 12533125]
37. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-Analysis. Lancet. 2009;373:746-58. [PMID: 19185342]
38. Biological therapies audit subgroup. National clinical audit report of biological therapies: UK Inflammatory Bowel Disease (IBD) audit. Adult national report. London, United Kingdom: Royal College of Physicians; 2013. Accessed at www.rcplondon.ac.uk/sites/default/files/nationalclinicalaudit-reportof- biological-therapies-Adult-report.-29august-2013.pdf on 20 February 2014.
39. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration [updated March 2011]; 2011. Accessed at http://handbook.cochrane.org on 20 February 2014.